An Open Label Randomized controlled trial comparing the effect of intravenous N Acetyl Cysteine infusion with standard care vs standard care alone on inflammatory markers and clinical outcomes in patients with burns involving 20 to 60 percentage BSA

Burns involving more than 20% BSA mount a significant inflammatory response leading to endothelial dysfunction, capillary leak and multi-organ complications

NAC, which is a potent anti-oxidant has been shown to reduce this inflammatory surge in various critical illnesses

However, its role in major burn patients remains inadequately studied with limited evidence on its effect on inflammatory markers

This study aims to evaluate whether intravenous NAC can attenuate systemic inflammation in patients with burns more than 20% BSA